Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 53, Issue 2, 2002, Pages 297-303

  Hanlon, Alexandra L ^a,b   Diratzouian, Hasmik ^b   Hanks, Gerald E ^b  

^a Department of Biostatistics ^*  (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Cause specific survival; Conformal radiotherapy; Distant metastasis; Prostate cancer; PSA nadir

Indexed keywords

ANTIGENS; BIOCHEMISTRY; DISEASES; DRUG DOSAGE; PATIENT TREATMENT; REGRESSION ANALYSIS; RISK ASSESSMENT; TUMORS;

MULTIVARIATE ANALYSES;

RADIOTHERAPY;

ANDROGEN; NADIR; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; REGRESSION ANALYSIS; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; REGRESSION ANALYSIS; TIME FACTORS; TREATMENT FAILURE;

EID: 0036603607     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02717-7     Document Type: Article

References (17)

1. Prostate
2. Outcome evaluation of the 1997 AJCC staging system for prostate carcinoma treated by radiation therapy
3. Defining the appropriate radiation dose for pretreatment PSA ≤10 ng/mL prostate cancer
4. Consensus statement: Guidelines for PSA following radiation therapy
5. Nonparametric estimation from incomplete observations
6. Evaluation of survival data and two new rank order statistics arising in its consideration
7. Validating a treatment policy for PSA failures following 3D conformal radiation therapy
8. The durability of external beam radiation therapy for prostate cancer: Can it be identified?
9. Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy
10. Predictive value of prostate specific antigen nadir after salvage cryotherapy
11. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome assessed systematic biopsy and serum prostate specific antigen
12. Prostate-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling time
13. Linear regressive analysis using PSA doubling time predicts tumor biology and clinical outcome in prostate cancer
14. Pretreatment prostate specific doubling times: Clinical utility of this predictor of prostate cancer behavior
15. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate